Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Zlatal 22.5mg/0.9ml inj pre-filled syringes
0801030P0BEABFF
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 18 |
|
Hydroxycarbamide 500mg/5ml oral suspension
0801050P0AAADAD
|
Hydroxycarbamide | Hydroxycarbamide | Malignant Disease and Immunosuppression | 17 |
|
Octreotide 500micrograms/1ml inj pre-filled syringes
0803043N0AAAQAQ
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 17 |
|
Tacrolimus 5mg modified-release capsules
0802020T0AAAPAP
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 17 |
|
Zlatal 12.5mg/0.5ml inj pre-filled syringes
0801030P0BEAFFJ
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 16 |
|
Rapamune 0.5mg tablets
0802020U0BBAFAF
|
Rapamune | Sirolimus | Malignant Disease and Immunosuppression | 15 |
|
Azathioprine 20mg/5ml oral suspension
0802010G0AACKCK
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 14 |
|
Sandimmun 50mg capsules
0802020G0BBAFAF
|
Sandimmun | Ciclosporin | Malignant Disease and Immunosuppression | 14 |
|
Tioguanine 40mg tablets
0801030T0AAAAAA
|
Tioguanine | Tioguanine | Malignant Disease and Immunosuppression | 14 |
|
Xromi 100mg/ml oral solution
0801050P0BDAAAE
|
Xromi | Hydroxycarbamide | Malignant Disease and Immunosuppression | 14 |
|
Dailiport 0.5mg modified-release capsules
0802020T0BKAAAM
|
Dailiport | Tacrolimus | Malignant Disease and Immunosuppression | 12 |
|
Somatuline LA 30mg inj vials
0803043P0BBAAAA
|
Somatuline | Lanreotide | Malignant Disease and Immunosuppression | 12 |
|
Tacrolimus 200microgram gran for susp sachets sugar free
0802020T0AAAVAV
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 12 |
|
Hydroxycarbamide 500mg/5ml oral solution
0801050P0AAABAB
|
Hydroxycarbamide | Hydroxycarbamide | Malignant Disease and Immunosuppression | 11 |
|
Mercaptopurine 25mg tablets
0801030L0AAAJAJ
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 11 |
|
Octreotide 100micrograms/1ml solution for injection vials
0803043N0AAALAL
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 11 |
|
Salvacyl 11.25mg inj vials
0803042W0BCAAAA
|
Salvacyl | Triptorelin | Malignant Disease and Immunosuppression | 11 |
|
Lanreotide 30mg inj vials
0803043P0AAAAAA
|
Lanreotide | Lanreotide | Malignant Disease and Immunosuppression | 10 |
|
Mercaptopurine 75mg tablets
0801030L0AAANAN
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 10 |
|
Skilarence 120mg gastro-resistant tablets
0802040AKBCABAD
|
Skilarence | Dimethyl fumar | Malignant Disease and Immunosuppression | 10 |
|
Xaluprine 20mg/ml oral suspension
0801030L0BCABAQ
|
Xaluprine | Mercaptopurine | Malignant Disease and Immunosuppression | 10 |
|
Sandostatin 50micrograms/1ml solution for injection ampoules
0803043N0BBAAAA
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 9 |
|
Tacrolimus 3mg modified-release capsules
0802020T0AAATAT
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 9 |
|
Tacrolimus 500microgram modified-release capsules
0802020T0AAAMAM
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 9 |
|
Azathioprine 10mg capsules
0802010G0AAAHAH
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 8 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.